OBJECTIVES: To investigate the serum level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific RBD IgG antibody (SARS-CoV-2 IgG antibody for short) in children with SARS-CoV-2 Omicron variant infection during the recovery stage, as well as the protective effect of SARS-CoV-2 vaccination against Omicron infection. METHODS: A retrospective analysis was performed on 110 children who were diagnosed with coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 Omicron variant infection in Tianjin of China from January 8 to February 7, 2022. According to the status of vaccination before diagnosis, they were divided into a booster vaccination (3 doses) group with 2 children, a complete vaccination (2 doses) group with 90 children, an incomplete vaccination (1 dose) group with 5 children, and a non-vaccination group with 13 children. The clinical data and IgG level were compared among the 4 groups. RESULTS: The complete vaccination group had a significantly higher age than the non-vaccination group at diagnosis (P<0.05), and there was a significant difference in the route of transmission between the two groups (P<0.05). There were no significant differences among the four groups in sex, clinical classification, and re-positive rate of SARS-CoV-2 nucleic acid detection (P>0.05). All 97 children were vaccinated with inactivated vaccine, among whom 85 children (88%) were vaccinated with BBIBP-CorV Sinopharm vaccine (Beijing Institute of Biological Products, Beijing, China). At 1 month after diagnosis, the booster vaccination group and the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05), and at 2 months after diagnosis, the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05). For the complete vaccination group, the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis was significantly lower than that at 1 month after diagnosis (P<0.05). CONCLUSIONS: Vaccination with inactivated SARS-CoV-2 vaccine has a protective effect against Omicron infection in children. For children vaccinated with 2 doses of the vaccine who experience Omicron infection, there may be a slight reduction in the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis. Citation:Chinese Journal of Contemporary Pediatrics, 2022, 24(7): 736-741.
OBJECTIVES: To investigate the serum level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific RBD IgG antibody (SARS-CoV-2 IgG antibody for short) in children with SARS-CoV-2 Omicron variant infection during the recovery stage, as well as the protective effect of SARS-CoV-2 vaccination against Omicron infection. METHODS: A retrospective analysis was performed on 110 children who were diagnosed with coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 Omicron variant infection in Tianjin of China from January 8 to February 7, 2022. According to the status of vaccination before diagnosis, they were divided into a booster vaccination (3 doses) group with 2 children, a complete vaccination (2 doses) group with 90 children, an incomplete vaccination (1 dose) group with 5 children, and a non-vaccination group with 13 children. The clinical data and IgG level were compared among the 4 groups. RESULTS: The complete vaccination group had a significantly higher age than the non-vaccination group at diagnosis (P<0.05), and there was a significant difference in the route of transmission between the two groups (P<0.05). There were no significant differences among the four groups in sex, clinical classification, and re-positive rate of SARS-CoV-2 nucleic acid detection (P>0.05). All 97 children were vaccinated with inactivated vaccine, among whom 85 children (88%) were vaccinated with BBIBP-CorV Sinopharm vaccine (Beijing Institute of Biological Products, Beijing, China). At 1 month after diagnosis, the booster vaccination group and the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05), and at 2 months after diagnosis, the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05). For the complete vaccination group, the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis was significantly lower than that at 1 month after diagnosis (P<0.05). CONCLUSIONS: Vaccination with inactivated SARS-CoV-2 vaccine has a protective effect against Omicron infection in children. For children vaccinated with 2 doses of the vaccine who experience Omicron infection, there may be a slight reduction in the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis. Citation:Chinese Journal of Contemporary Pediatrics, 2022, 24(7): 736-741.
Authors: Eric Salazar; Suresh V Kuchipudi; Paul A Christensen; Todd Eagar; Xin Yi; Picheng Zhao; Zhicheng Jin; S Wesley Long; Randall J Olsen; Jian Chen; Brian Castillo; Christopher Leveque; Dalton Towers; Jason Lavinder; Jimmy Gollihar; Jose Cardona; Gregory Ippolito; Ruth Nissly; Ian Bird; Denver Greenawalt; Randall M Rossi; Abhinay Gontu; Sreenidhi Srinivasan; Indira Poojary; Isabella M Cattadori; Peter J Hudson; Nicole M Josleyn; Laura Prugar; Kathleen Huie; Andrew Herbert; David W Bernard; John M Dye; Vivek Kapur; James M Musser Journal: J Clin Invest Date: 2020-12-01 Impact factor: 14.808
Authors: Anita S Iyer; Forrest K Jones; Ariana Nodoushani; Jason B Harris; Richelle C Charles; Meagan Kelly; Margaret Becker; Damien Slater; Rachel Mills; Erica Teng; Mohammad Kamruzzaman; Wilfredo F Garcia-Beltran; Michael Astudillo; Diane Yang; Tyler E Miller; Elizabeth Oliver; Stephanie Fischinger; Caroline Atyeo; A John Iafrate; Stephen B Calderwood; Stephen A Lauer; Jingyou Yu; Zhenfeng Li; Jared Feldman; Blake M Hauser; Timothy M Caradonna; John A Branda; Sarah E Turbett; Regina C LaRocque; Guillaume Mellon; Dan H Barouch; Aaron G Schmidt; Andrew S Azman; Galit Alter; Edward T Ryan Journal: Sci Immunol Date: 2020-10-08
Authors: Maria Prendecki; Candice Clarke; Jonathan Brown; Alison Cox; Sarah Gleeson; Mary Guckian; Paul Randell; Alessia Dalla Pria; Liz Lightstone; Xiao-Ning Xu; Wendy Barclay; Stephen P McAdoo; Peter Kelleher; Michelle Willicombe Journal: Lancet Date: 2021-02-25 Impact factor: 79.321
Authors: Tommy Nyberg; Neil M Ferguson; Sophie G Nash; Harriet H Webster; Seth Flaxman; Nick Andrews; Wes Hinsley; Jamie Lopez Bernal; Meaghan Kall; Samir Bhatt; Paula Blomquist; Asad Zaidi; Erik Volz; Nurin Abdul Aziz; Katie Harman; Sebastian Funk; Sam Abbott; Russell Hope; Andre Charlett; Meera Chand; Azra C Ghani; Shaun R Seaman; Gavin Dabrera; Daniela De Angelis; Anne M Presanis; Simon Thelwall Journal: Lancet Date: 2022-03-16 Impact factor: 202.731
Authors: Zijun Wang; Frauke Muecksch; Dennis Schaefer-Babajew; Shlomo Finkin; Charlotte Viant; Christian Gaebler; Hans- Heinrich Hoffmann; Christopher O Barnes; Melissa Cipolla; Victor Ramos; Thiago Y Oliveira; Alice Cho; Fabian Schmidt; Justin Da Silva; Eva Bednarski; Lauren Aguado; Jim Yee; Mridushi Daga; Martina Turroja; Katrina G Millard; Mila Jankovic; Anna Gazumyan; Zhen Zhao; Charles M Rice; Paul D Bieniasz; Marina Caskey; Theodora Hatziioannou; Michel C Nussenzweig Journal: Nature Date: 2021-06-14 Impact factor: 49.962
Authors: Antonio E Muruato; Camila R Fontes-Garfias; Ping Ren; Mariano A Garcia-Blanco; Vineet D Menachery; Xuping Xie; Pei-Yong Shi Journal: Nat Commun Date: 2020-08-13 Impact factor: 14.919